Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
US4525EP1011
Wed, 13.11.2024
Immunic AG
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
– Includes Phase 1 Data in Healthy Human Subjects and
Phase 1b Data in Celiac Disease Patients –
NEW YORK, November 13, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developi [ … ]
Thu, 07.11.2024
Immunic AG
Immunic, Inc. Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned –
– Ongoing, Twin Phase 3 ENSURE Trials [ … ]
Thu, 31.10.2024
Immunic AG
Immunic, Inc. to Announce Financial Results for the Third Quarter EndedSeptember 30, 2024, and Provide Corporate Update
– Webcast to be Held at 8:00 am ET on November 7, 2024 –
NEW YORK, October 31, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chro [ … ]
Tue, 29.10.2024
Immunic AG
Immunic to Participate in Industry, Scientific and Investor Conferences in November
NEW YORK, October 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following indus [ … ]
Tue, 22.10.2024
Immunic AG
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met –
– IDMC Also Recommended Continuing Trial without Change [ … ]
Wed, 18.09.2024
Immunic AG
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P [ … ]
Wed, 18.09.2024
Immunic AG
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P [ … ]
Wed, 04.09.2024
Immunic AG
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic –
– In Addition to Post COVID Rea [ … ]
Wed, 28.08.2024
Immunic AG
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that t [ … ]
Thu, 08.08.2024
Immunic AG
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President –
– Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceuti [ … ]